Arsanis (ASNS) Stock Price, News & Analysis

Company Overview

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $1.29 to $1.39
• 50-Day Range: $3.11 to $3.11
• 52-Week Range: $1.15 to $28.69
• Volume: 1.73 million shs
• Average Volume: 309,501 shs
• Market Capitalization: $7.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Arsanis Stock Analysis - MarketRank™

Arsanis scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Arsanis.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Arsanis is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arsanis is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arsanis has a P/B Ratio of 16.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.15% of the float of Arsanis has been sold short.

Short Interest Ratio / Days to Cover

Arsanis has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arsanis has recently decreased by 1.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arsanis does not currently pay a dividend.

Dividend Growth

Arsanis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.15% of the float of Arsanis has been sold short.

Short Interest Ratio / Days to Cover

Arsanis has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Arsanis has recently decreased by 1.51%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 3 news articles for Arsanis this week, compared to 1 article on an average week.

Search Interest

Only 3 people have searched for ASNS on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arsanis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Arsanis is held by insiders.

Percentage Held by Institutions

Only 12.43% of the stock of Arsanis is held by institutions.

ASNS Stock Analysis - Frequently Asked Questions

How were Arsanis' earnings last quarter?

Arsanis, Inc. (NASDAQ:ASNS) announced its quarterly earnings data on Wednesday, August, 14th. The company reported $0.01 EPS for the quarter. The firm had revenue of $3.43 million for the quarter. Arsanis had a negative net margin of 78.75% and a negative trailing twelve-month return on equity of 5,659.70%.

When did Arsanis' stock split?

Shares of Arsanis reverse split on the morning of Wednesday, April 19th 2023. The 1-10 reverse split was announced on Wednesday, April 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Arsanis IPO?

Arsanis (ASNS) raised $15 million in an initial public offering (IPO) on Friday, May 13th 2022. The company issued 3,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO.

What other stocks do shareholders of Arsanis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arsanis investors own include NVIDIA (NVDA), Catalyst Pharmaceuticals (CPRX), Meta Platforms (META), Vanguard FTSE Developed Markets ETF (VEA), ARK Innovation ETF (ARKK), Vanguard Total Bond Market ETF (BND) and iShares Core S&P 500 ETF (IVV).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 10/15/2024
• Next Earnings (Estimated): 11/12/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Computer and Technology
• Industry: Communications equipment, not elsewhere classified
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ASNS
• CUSIP: N/A
• CIK: 1501697
• Web: www.arsanis.com
• Phone: (857) 529-8300
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,290,000.00
• Net Margins: -78.75%
• Pretax Margin: -80.54%
• Return on Equity: -5,659.70%
• Return on Assets: -45.96%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 1.01
• Quick Ratio: 0.68

Sales & Book Value

• Annual Sales: $5.61 million
• Price / Sales: 1.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 17.13

Miscellaneous

• Outstanding Shares: 6,020,000
• Free Float: 5,687,000
• Market Cap: $8.25 million
• Optionable: Not Optionable
• Beta: 2.09